The Task Force will host a workshop in the Spring 2018 that will bring together stakeholders to discuss topics including:
This workshop will last two days and be held back-to-back with a two-day workshop from the Biomarkers Task Force in May 2018. Participants are welcome to attend all four days of presentations and break-out session discussions.
Stay tuned in 2018 for dates, location and registration information to be shared by SITC.
Francesco Marincola, MDAbbvie Inc.
Josue Samayoa, PhDAbbvie Biotherapeutics
Stefanie Spranger, PhDKoch Institute for Integrative Cancer Research at MIT
The majority of NSCLC patients do not still respond to PD-1/PD-L1 treatment. Chemotherapy is theorized to increase the release of tumor antigen resulting in increased response with immunotherapy. But cytotoxic chemotherapy can also destroy actively proliferating ...
more details in our latest news story: bit.ly/2CpnCWQ ------------------------------ Jade Parker Editor Future Science Group ------------------------------
Course Name: 6 th Annual Lung Cancer Symposium
Course Date: Friday, March 2, 2018
Course Co-Directors and Planners : Ralph Zinner, MD; Gregory Kane, MD; Judith Alberto, RPh; Rita Axelrod, MD; Stephanie Bork, MSN, CRNP; Nathaniel R. Evans III, ...
This message was posted by a user wishing to remain anonymous Hi All His is an attempt to find answers on the observed onset of effect on Opdivo / Nivolumab treatment. If you are a doctor having experience with this treatment I would be eager to hear ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org